Minichromosome maintenance proteins in lung adenocarcinoma: Clinical significance and therapeutic targets.
MCM
lung adenocarcinoma
miR-139-3p
miR-2110
miR-378a-5p
simurosertib
Journal
FEBS open bio
ISSN: 2211-5463
Titre abrégé: FEBS Open Bio
Pays: England
ID NLM: 101580716
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
29
06
2023
received:
01
04
2023
accepted:
27
07
2023
medline:
5
9
2023
pubmed:
30
7
2023
entrez:
30
7
2023
Statut:
ppublish
Résumé
Lung cancer is the most common cause of cancer-related death worldwide, accounting for 1.8 million deaths annually. Analysis of The Cancer Genome Atlas data showed that all members of the minichromosome maintenance (MCM) family (hexamers involved in DNA replication: MCM2-MCM7) were upregulated in lung adenocarcinoma (LUAD) tissues. High expression of MCM4 (P = 0.0032), MCM5 (P = 0.0032), and MCM7 (P = 0.0110) significantly predicted 5-year survival rates in patients with LUAD. Simurosertib (TAK-931) significantly suppressed the proliferation of LUAD cells by inhibiting cell division cycle 7-mediated MCM2 phosphorylation. This finding suggested that MCM2 might be a therapeutic target for LUAD. Moreover, analysis of the epigenetic regulation of MCM2 showed that miR-139-3p, miR-378a-5p, and miR-2110 modulated MCM2 expression in LUAD cells. In patients with LUAD, understanding the role of these miRNAs may improve prognoses.
Identifiants
pubmed: 37517032
doi: 10.1002/2211-5463.13681
pmc: PMC10476565
doi:
Substances chimiques
Minichromosome Maintenance Proteins
EC 3.6.4.12
MicroRNAs
0
MIRN139 microRNA, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1737-1755Informations de copyright
© 2023 The Authors. FEBS Open Bio published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
FEBS J. 2008 Oct;275(20):4929-44
pubmed: 18754771
J Microbiol Biotechnol. 2022 Jul 28;32(7):918-926
pubmed: 35880481
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
EMBO J. 1999 Oct 15;18(20):5703-13
pubmed: 10523313
Cancer. 2001 Dec 15;92(12):3051-5
pubmed: 11753983
Transl Lung Cancer Res. 2016 Feb;5(1):26-38
pubmed: 26958491
Lancet. 2017 Jul 1;390(10089):29-39
pubmed: 28501140
Cancer Manag Res. 2017 Nov 15;9:637-647
pubmed: 29180899
Curr Cancer Drug Targets. 2005 Aug;5(5):365-80
pubmed: 16101384
Cancer Res. 2010 Apr 1;70(7):2809-18
pubmed: 20332239
Cancer Metastasis Rev. 2018 Mar;37(1):33-44
pubmed: 29282605
Clin Cancer Res. 2010 Sep 15;16(18):4503-8
pubmed: 20647475
Clin Cancer Res. 2008 Jan 15;14(2):435-45
pubmed: 18223218
Oncol Lett. 2021 Jul;22(1):539
pubmed: 34084218
Lung Cancer. 2010 Mar;67(3):296-300
pubmed: 19473720
Adv Cancer Res. 2016;132:165-207
pubmed: 27613133
Genes Dev. 2009 Mar 1;23(5):643-54
pubmed: 19270162
Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W741-8
pubmed: 15980575
Anticancer Res. 2011 Sep;31(9):3027-33
pubmed: 21868554
Int J Mol Sci. 2019 Sep 11;20(18):
pubmed: 31514295
FEBS J. 2009 Jun;276(12):3382-91
pubmed: 19438708
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
Sci Adv. 2019 May 22;5(5):eaav3660
pubmed: 31131319
Eur J Pharmacol. 2003 Feb 21;462(1-3):15-23
pubmed: 12591091
Curr Opin Genet Dev. 2001 Feb;11(1):64-70
pubmed: 11163153
Nucleic Acids Res. 2021 Jan 8;49(D1):D613-D621
pubmed: 33211851
Pharmacol Res. 2022 Apr;178:106162
pubmed: 35259479
Cell Biosci. 2018 Jul 24;8:43
pubmed: 30062004
J Exp Clin Cancer Res. 2020 Oct 28;39(1):225
pubmed: 33109220
Cancers (Basel). 2021 Mar 10;13(6):
pubmed: 33801812
Oncotarget. 2017 Jun 20;8(25):40501-40513
pubmed: 28465488
Biomedicines. 2022 Mar 03;10(3):
pubmed: 35327392
Lung Cancer. 2018 Jul;121:12-17
pubmed: 29858020
Bioessays. 2003 Dec;25(12):1158-67
pubmed: 14635251
Cells. 2020 Sep 11;9(9):
pubmed: 32932948
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
Genes Cells. 2003 May;8(5):413-21
pubmed: 12694531
Nat Rev Genet. 2008 Feb;9(2):102-14
pubmed: 18197166
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Sci Rep. 2017 Dec 5;7(1):17024
pubmed: 29209046
Oncotarget. 2017 Jun 13;8(24):39209-39217
pubmed: 28424404
Biomed Pharmacother. 2017 Sep;93:103-116
pubmed: 28628830
Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11521-6
pubmed: 16864800
Cell Cycle. 2014;13(12):1859-66
pubmed: 24841992
Front Oncol. 2021 Dec 21;11:782755
pubmed: 34993142
Cell Mol Life Sci. 2016 Aug;73(15):2829-50
pubmed: 26791483
Biomed Res Int. 2014;2014:549719
pubmed: 25243149
Biosci Rep. 2013 Oct 07;33(5):
pubmed: 24001138
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Anticancer Res. 2011 Oct;31(10):3585-94
pubmed: 21965782
Genes Genet Syst. 2018 Nov 10;93(4):125-133
pubmed: 30369561
Cancer Cell. 2013 Jun 10;23(6):796-810
pubmed: 23764002
Mol Biotechnol. 2022 Jul;64(7):832-840
pubmed: 35150405
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008
Cancer Lett. 2022 Jul 28;539:215677
pubmed: 35490917
Anal Cell Pathol (Amst). 2020 Feb 3;2020:3750294
pubmed: 32089988
Oncol Rep. 2015 May;33(5):2599-605
pubmed: 25738322
J Thorac Oncol. 2016 Oct;11(10):1653-71
pubmed: 27364315
Elife. 2015 Aug 12;4:
pubmed: 26267216